ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.

Yuta MyojinTakahiro KodamaKazuki MaesakaDaisuke MotookaYu SatoSatoshi TanakaYuichi AbeKazuyoshi OhkawaEiji MitaYoshito HayashiHayato HikitaRyotaro SakamoriTomohide TatsumiAyumu TaguchiHidetoshi EguchiTetsuo Takehara

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Serum ST6GAL may be a novel biomarker that identifies lenvatinib-susceptible FGF19-driven HCC.

Keyphrases

genome wide
gene expression